Skip to content


  • Review
  • Open Access

The role of melatonin in the onset and progression of type 3 diabetes

Molecular Brain201710:35

  • Received: 17 January 2017
  • Accepted: 12 July 2017
  • Published:

The Correction to this article has been published in Molecular Brain 2017 10:59


Alzheimer’s disease (AD) is defined by the excessive accumulation of toxic peptides, such as beta amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFT). The risk factors associated with AD include genetic mutations, aging, insulin resistance, and oxidative stress. To date, several studies that have demonstrated an association between AD and diabetes have revealed that the common risk factors include insulin resistance, sleep disturbances, blood brain barrier (BBB) disruption, and altered glucose homeostasis. Many researchers have discovered that there are mechanisms common to both diabetes and AD. AD that results from insulin resistance in the brain is termed “type 3 diabetes”. Melatonin synthesized by the pineal gland is known to contribute to circadian rhythms, insulin resistance, protection of the BBB, and cell survival mechanisms. Here, we review the relationship between melatonin and type 3 diabetes, and suggest that melatonin might regulate the risk factors for type 3 diabetes. We suggest that melatonin is crucial for attenuating the onset of type 3 diabetes by intervening in Aβ accumulation, insulin resistance, glucose metabolism, and BBB permeability.


  • Melatonin
  • Type 3 diabetes
  • Alzheimer’s disease (AD)
  • Insulin resistance
  • Hyperglycemia
  • Blood brain barrier (BBB)
  • Beta amyloid (Aβ)


Alzheimer’s disease (AD) is an age-related neurodegenerative disorder that is characterized by the abnormal aggregation and accumulation of toxic peptides resulting in beta amyloid (Aβ) plaques and intracellular neurofibrillary tangles (NFT) [1]. According to recent reports, the number of patients with AD will be over 13.8 million by 2050, which will place a tremendous burden on society globally [24]. The onset of AD is linked to various causes, such as genetic mutations [5, 6], sex [7], lipid metabolism [811], aging [1214], and diet [9, 15]. AD pathology results from excessive oxidative stress, synaptic loss, neuronal cell death, impaired insulin signaling, and abnormal glucose metabolism [1618]. Cohort studies have demonstrated that type 2 diabetes (T2DM) increases the risk of dementia and results from common risk factors associated with dementia, including insulin resistance and hyperglycemia [19]. Many patients with metabolic diseases, such as cardiovascular disease, diabetes, and obesity, are reported to have a progressive decline in cognitive function, leading to the development of AD [20, 21]. One meta-analysis showed that diabetes significantly increases the risk for AD in elderly people [22]. Owing to the common risk factors between diabetes and AD, recent studies have proposed that AD is a brain-specific type of diabetes, which they termed “type 3 diabetes” [17, 2325].

Melatonin (N-acetyl-5-methoxytryptamine) is mainly secreted as a neurohormone by the pineal gland [26]. It plays a role in various physiological functions, including circadian rhythm regulation, antioxidant activities, and the regulation of mitochondrial function [2730]. Given that sleep disorders frequently occur in up to 45% of patients with AD [3133], melatonin is an important hormone for the treatment of AD since it corrects abnormal sleep patterns [34, 35]. In AD, melatonin levels are decreased in the cerebrospinal fluid (CSF) compared to those in the normal population [36, 37]. Several studies have demonstrated that melatonin reduces Aβ accumulation [38], tau hyperphosphorylation [39], synaptic dysfunction [40], and blood brain barrier (BBB) permeability [41]. Moreover, melatonin attenuates insulin resistance [42], and regulates glucose homeostasis [43, 44]. In this review, we summarize the therapeutic functions of melatonin in type 3 diabetes from various perspectives.

The risk factors for diabetes contribute to the onset and progression of Alzheimer’s disease

Insulin resistance leads to cognitive decline

Diabetes is characterized by insulin resistance, diminished pancreatic beta-cell function, and abnormally high glucose levels [45]. Diabetes is commonly classified into two types, namely, type 1 (T1DM) and T2DM [45]. T2DM occurs more frequently in the global population than T1DM and is accompanied by insulin resistance, hyperglycemia, cognitive decline, and impaired circadian rhythms [46, 47]. T2DM is known to be associated with cognitive impairments [48], and is commonly used as an index for the development of vascular dementia [49], and AD [50, 51]. The high prevalence of central nervous system (CNS) diseases in patients with diabetes has already been revealed by global reports [5255]. The onset and progression of AD is associated with the capacity of the brain to utilize glucose for energy production [56, 57]. In the CNS, insulin signaling plays central roles in the cognitive dysfunction found in AD [58]. Insulin is known to be neuroprotective and has powerful effects on memory [59]. Previous studies have shown that deficiencies in insulin receptors (IRs) in the brain, a factor implicated in insulin resistance, leads to memory dysfunction [18, 60]. IRs are localized in cerebral regions, such as the hippocampus, amygdala, and septum [61, 62]. AD patients show an 80% reduction in IRs in their brains compared to normal subjects [17]. Consequently, insulin signaling is abnormal [63]. Some studies have demonstrated that the hippocampus regulates the consolidation of memory via insulin signaling [64, 65]. Based on this evidence, decreased insulin levels were subsequently found in the CSF of patients with AD and mild cognitive impairment (MCI) [60, 66, 67]. Aβ accumulation, abnormalities in the cholinergic system, tau hyperphosphorylation, and damage to neuronal cells contributes to impaired insulin signaling [68, 69]. Insulin receptors deficiency in the AD brain results in insulin resistance in AD neuropathology [18, 70]. For these reasons, reduced levels of insulin receptor genes may contribute to the progression of AD [23, 71]. Moreover, tau pathology in AD is mediated by impaired tau gene expression owing to the attenuation in insulin signaling [72, 73]. Insulin resistance in the AD brain reduces the phosphorylation of phosphoinositol-3-kinase (PI3K), and Akt [72, 73], which ordinarily function to promote neuronal growth and survival, and promotes GABAergic transmission involved in learning and memory [74], and blocks the accumulation of Aβ [75]. Additionally, insulin resistance increases the activation of glycogen synthase kinase (GSK-3) [76, 77], which is related to the hyperphosphorylation of tau and the acceleration of tau misfolding [78]. Indeed, owing to deficiencies in insulin, the change of GSK-3 activity leads to the hyperphosphorylation of tau [79], perhaps unsurprising given what we know about the aberrant activation of GSK-3β and the resultant Aβ accumulation and tau protein phosphorylation [80, 81]. Moreover, several clinical studies have demonstrated a positive correlation between diabetes and AD [57, 82], and suggested that the central reasons for this include aberrant insulin signaling and dementia [58, 8385]. In in vivo studies, an AD mouse model showed insulin resistance [24], reduced glucose metabolism, oxidative stress, and cognitive impairments [86] following injections of streptozotocin (STZ). In addition, insulin resistance leads to hippocampal neuronal loss owing to amyloid neurotoxicity [68], reduced glucose uptake by inhibiting the expression of glucose transporters in cell membrane [87], and accelerated amyloid aggregation during early AD [88]. Consequently, insulin resistance and impaired insulin signaling are significantly related to tau hyperphosphorylation and Aβ deposition in AD, and ultimately contribute to cognitive decline [69] (Fig. 1).
Fig. 1
Fig. 1

Insulin resistance triggers cognitive decline. Insulin resistance increases p-GSK3β phosphorylation, tau hyperphosphorylation, Aβ aggregation and reduces p-AKT phosphorylation, leading to cognitive deficits

Hyperglycemia triggers BBB disruption leading to cognitive dysfunction

According to previous studies, hyperglycemia in T2DM leads to cognitive dysfunction [8991]. An abnormal glycemic condition is one of the main causes of BBB breakdown in patients with diabetes [92, 93]. Several studies demonstrated that the loss of tight junction proteins which make up the BBB and the activation of matrix metalloproteinases (MMPs) was shown in hyperglycemia in vivo model [94] and in patients [95, 96]. The BBB is comprised of brain endothelial cells lining the cerebral microvessels with astrocytic end-feet processes. The BBB endothelium is characterized by specific transmembrane transport systems that control the trafficking of small molecules in and out of the brain parenchyma [97]. Glucose, the primary energetic source in the brain, can cross the BBB through transporter proteins, such as facilitative sodium independent transporters (e.g., the glucose transporter [GLUT]) [98, 99]. One animal study has shown downregulation of BBB glucose transporters in hyperglycemic mice compared to wild-type mice [100]. In chronic hyperglycemia conditions, GLUT1 and GLUT3 expression was attenuated in diabetic animal brain and subsequently aberrant GLUT’s expression triggers neuronal cell damage [100]. In addition, many studies have reported that the BBB in the diabetic brain has increased permeability owing to the activation of hypoxia-inducible factor-1α (HIF-1α) and increased levels of vascular endothelial growth factor (VEGF) [101, 102]. Hyperglycemia promotes the production of reactive oxygen species (ROS) [103, 104] and downregulates glucose transporters in brain endothelial cells [105]. Moreover, hyperglycemia aggravates amyloid toxicity, independent of insulin resistance [106]. Numerous studies have demonstrated that diet-induced hyperglycemia triggers an increase in BBB permeability and BBB damage [107]. The expression of IgG as the marker of BBB permeability was increased and tight junction proteins were attenuated in a hyperglycemia model [107]. In AD, BBB disruption promotes tau hyperphosphorylation [108, 109]. BBB disruption decreases the expression of glucose transporters [110], promotes ROS production [111] and increases infiltration of inflammatory mediators [112]. Tau aggregation is associated with increase of inflammation [112] and reduction of glucose transporters [110]. In addition, BBB dysfunction in AD contributes to Aβ clearance, activates glial cells, and aggravates inflammation by recruiting leukocytes to the brain [113]. Given this evidence, hyperglycemia-induced BBB disruption might play an important role in the onset and progression of AD (Fig. 2).
Fig. 2
Fig. 2

Hyperglycemia leads to cognitive decline. Hyperglycemia aggravate BBB breakdown, and increase the generation of ROS, inflammatory response, and Aβ aggregation, ultimately leading to cognitive decline

Melatonin in AD

Melatonin has been shown to have neuroprotective effects in a mouse model of AD [114, 115], since it attenuates Aβ accumulation and synaptic dysfunction by stabilizing the mitochondria function and inhibiting DNA damage [38, 40]. Melatonin controls several molecular signaling pathways, such as PI3/Akt/GSk3β and hemooxygenase-1 [39, 116, 117], and free radical scavenging mechanisms [118, 119] in the AD brain. A recent study demonstrated that melatonin improves synapse dysfunction via the Notch1/Hes1 signaling pathway in the hippocampus [120]. Another study suggested that melatonin inhibits apoptotic mediators and promotes pro-survival signaling in a model of AD [121]. An animal study demonstrated that chronic melatonin treatment for 30 days improves memory impairments in the AD mouse model [117]. Moreover, in patients with AD, melatonin levels were significantly decreased in the serum and CSF, and levels of melatonin were considered as a candidate risk factor for diagnosis of AD [37, 122]. Clinically, melatonin and its agonist have been regarded as treatments for AD [123, 124]. As mentioned above, melatonin has the potential to attenuate AD pathology via numerous mechanisms including PI3K/Akt/GSK3β [37] and Notch1 signaling [120], and RAGE/NF-κB/JNK signaling pathway [117]. Future study of the specific mechanisms of melatonin in the CNS is necessary to identify potential therapeutic solutions for AD.

The relationship between melatonin and type 3 diabetes

Melatonin protects cells against Aβ toxicity and inhibits tau hyperphosphorylation

Aβ, the main component of amyloid plaques, is believed to cause memory dysfunction [125]. Melatonin improves soluble Aβ-induced memory dysfunction and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway [120], suggesting that the modulation of Notch1 could restore neurogenesis and cognitive function in AD models [126]. According to the results of an in vivo study, melatonin administration inhibits the expression of amyloid precursor protein-cleaving secretases in the hippocampus [127]. In addition, melatonin attenuates the memory impairments induced by Aβ accumulation in a sporadic AD model [38, 128, 129]. Melatonin inhibits the transcription of β-secretases via the melatonin receptors in SH-SY5Y neuronal cells [130]. Melatonin attenuates Aβ-induced memory dysfunction and tau hyperphosphorylation via the PI3/Akt/GSK3β pathway in the mouse brain [39]. Melatonin suppresses the activity of GSK3β through activation of p-GSK3β (Ser9) in Aβ in vitro model [131]. Moreover, it improves Aβ-induced impairments in hippocampal long-term potentiation (LTP) in rats [132]. Melatonin inhibits superoxide anion production in microglia under conditions of Aβ toxicity [115]. In addition, it inhibits memory dysfunction and tau phosphorylation in rats [133]. Considering the effect of melatonin on Aβ toxicity and tau hyperphosphorylation in AD, melatonin may be a key to improving memory function by suppressing the cell damage induced by Aβ toxicity and tau hyperphosphorylation.

Melatonin protects cells against insulin resistance and hyperglycemia

Diabetes is accompanied by dysregulation of the circadian system [134]. This is interesting given that glucose metabolism is regulated by the circadian system [135, 136]. In animals and humans with diabetes, increased insulin levels and abnormal glucose metabolism triggers aberrant circadian rhythms [42, 137]. One study demonstrated that a reduction of melatonin levels in serum is linked with high insulin levels in T2DM rats [42]. Moreover, Sakotnik et al. suggested that polymorphisms in the melatonin receptor gene are related to fasting blood glucose levels and increases in the prevalence of T2DM [138]. Several genome wide studies have shown that specific single nucleotide polymorphisms of the melatonin receptor 2 (MTNR1B) locus are related to the high glucose levels found in T2DM [139141]. Genome-wide studies have shown that allelic variations in the melatonin receptor 2 (MT2) contribute to the elevations in fasting glucose levels in plasma, insulin resistance, and ultimately the risk for type 2 diabetes [142, 143]. Type 3 diabetes is related to the prevalence of T2DM and results from insulin resistance and hyperglycemia [144146]. Therefore, a method of reducing the cell damage induced by insulin resistance and hyperglycemia is crucial in both diabetes and AD. Melatonin activates the expression of the MT2 receptor, which can inhibit the secretion of insulin from pancreatic β-cells [147, 148]. Numerous studies have shown that melatonin contributes to glucose homeostasis and that low glucose levels are present in patients with T2DM [137, 149]. A recent study has shown that loss of the melatonin receptor contributes to the activation of pancreatic islet hormones, and hepatic glucose transporters (Glut1 and 2) [150]. Melatonin attenuates the glucose-mediated release of insulin from pancreatic cells [151]. The reduction in melatonin secretion induced by nocturnal light exposure is a crucial factor for T2DM development [136, 152, 153]. Furthermore, the melatonin receptor 1 (MT1) is involved in the regulation of glucose homeostasis and stimulates the secretion of insulin to induce glucose uptake [43]. In humans, melatonin administration attenuates glucose tolerance and insulin resistance [44]. Melatonin could suppress mitochondrial dysfunction against insulin resistance in Male Zucker diabetic fatty rats [154]. Furthermore, melatonin attenuates the secretion of pro inflammatory cytokines such as interleukin-6 (IL-6), tumor necrosis factor (TNF)-α, interferon (IFN)-gamma under insulin resistance condition in high fat diet mouse [155]. Melatonin is associated with metabolic pathways involved with the insulin pathway [156158]. The phosphorylation of IRS-1, leading to the activation of phosphoinositide 3-kinase (PI-3 K), and SHP-2 protein was increased by melatonin [159, 160]. In the AD brain, the disturbance of insulin signaling is linked to the senile plaques formation [80, 161]. An impaired insulin receptor signaling triggers the decrease of insulin-mediated activation of PI-3 K/Akt signaling, resulting in hyperactivity of GSK-3 that induces tau hyperphosphorylation and Aβ accumulation [162]. The administration of melatonin rescues insulin receptor mechanisms and increases the activity of PI-3 K/Akt signaling and less Aβ accumulation and less tau hyperphosphorylation [163] (Fig. 3). One study suggested that the lack of melatonin by pinealectomy reduced insulin sensitivity [164]. The reduction of insulin levels in T1DM are linked to high melatonin levels in plasma [165]. Taking these results together, melatonin appears to be involved in the genesis of diabetes [42] accompanied by insulin resistance and high glucose, and may influence the cognitive dysfunction in diabetes-induced AD (Fig. 4). In this sense, melatonin may be a key molecule in the pathogenesis of Type 3 diabetes.
Fig. 3
Fig. 3

Melatonin restores the disruption of insulin signaling in AD. In insulin resistance condition, melatonin activates PI3K/Akt signaling, leading to the decrease of tau hyperphosphorylation and Aβ accumulation

Fig. 4
Fig. 4

Melatonin improve cognitive decline by regulating insulin resistance and hyperglycemia. Melatonin controls insulin resistance and glucose metabolism. Melatonin increases the expression of glucose transporters such as Glut1 and Glut2. Also, melatonin increase the secretion of insulin and protects cell damage, and reduces glial reactivity. Finally, melatonin improves cognitive decline in AD brain

Melatonin protects the BBB against hyperglycemia

Several studies have shown that disruption of the BBB is strongly associated with cognitive dysfunction in AD [166, 167]. The BBB is a heterogeneous structure that consists of various cells important for transferring nutrients and oxygen into brain, and disruption of the BBB has been observed in patients with T2DM [168, 169]. Increases in glucose levels in the blood leads to impaired neurovascular coupling [170, 171], and increased vascular permeability [172]. Hyperglycemia-induced increases in BBB permeability lead to cognitive decline and the development of AD [101]. Hyperglycemia-induced ROS results in BBB disruption and triggers cognitive decline [101]. Dysfunction of metabolic pathways, owing to BBB disruption in diabetes, leads to cognitive deficits [173, 174]. In an in vivo study, STZ-induced diabetes results in increased BBB permeability [101]. Impaired BBB function in diabetes may be a strong risk factor for the development of AD [175, 176]. The excessive generation of ROS in T2DM has been shown to increase BBB permeability by changing tight junction protein expression [177, 178]. According to recent studies, melatonin protects BBB integrity in brain microvascular endothelial cells against inflammation [179], and protects against cerebral endothelial cell dysfunction via nicotinamide adenine dinucleotide phosphate (NADPH) oxidase-2 [180]. Moreover, melatonin prevents the increase in BBB permeability by inhibiting matrix metalloproteinase-9 expression [41]. In addition, melatonin protects against the loss of tight junction proteins and BBB disruption by promoting anti-inflammatory and antioxidant mediators, and axonal regrowth [29]. Melatonin reduces the oxidative stress-induced generation of ROS in brain endothelial cells [181], and ameliorates BBB permeability and nitric oxide levels caused by oxidative stress [182, 183]. In addition, melatonin protects against the degradation of tight junction proteins, BBB disruption, serves as an anti-inflammatory and angiogenesis regulator, and promotes axonal regrowth under high glucose conditions [29, 184]. Based on previous reports, melatonin might alleviate BBB breakdown in diabetes-induced AD by inhibiting the loss of tight junction and the increase of BBB permeability (Fig. 5).
Fig. 5
Fig. 5

Melatonin improves cognitive decline by inhibiting BBB breakdown. Melatonin inhibits the production of ROS and the vascular permeability and increases axonal regrowth. Melatonin suppresses BBB breakdown and enhances cognitive decline

Conclusions and prospects

Diabetes-induced AD has been called “type 3 diabetes” owing to the common risk factors, which include insulin resistance and hyperglycemia. Here, we reviewed the effect of melatonin in type 3 diabetes from various angles. Melatonin influences type 3 diabetes by 1) suppressing Aβ toxicity and tau hyperphosphorylation, 2) controlling insulin resistance and hyperglycemia, and 3) preventing hyperglycemia-induced BBB disruption. Hence, we suggest that melatonin would be a key in attenuating the pathogenesis of type 3 diabetes.




Alzheimer’s disease


Beta amyloid


Blood brain barrier


Central nervous system


Cerebrospinal fluid


Glucose transporter


Glucose transporter 1


Glycogen synthase kinase


Hypoxia-inducible factor-1α


interferon –gamma




Insulin receptors


Mild cognitive impairment


Melatonin receptor 1


Intracellular neurofibrillary tangles




Reactive oxygen species




Type 1 diabetes


Type 2 diabetes


tumor necrosis factor-α


Vascular endothelial growth factor



This study was supported by the Brain Research Program through the National Research Foundation of Korea funded by the Ministry of Science, ICT & Future Planning NRF-2016M3C7A1905469 (B.K.) and a grant from 2016R1D1A1B03930394 (J.S.).


All sources of funding (the Ministry of Science, ICT & Future Planning NRF-2016M3C7A1905469 & - 2016R1D1A1B03930394) for the research declare the support of the funding in collecting references and in writing the manuscript.

Availability of data and materials

Not applicable.

Authors’ contributions

JS contributed to writing the preliminary draft of this manuscript. DJW revised the overall manuscript with a logical argument. BCK revised the manuscript as a whole. All authors read and approved the final manuscript.

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Authors’ Affiliations

Department of Biomedical Sciences, Center for Creative Biomedical Scientists at Chonnam National University, Gwangju, 61469, South Korea
Henry Wellcome Laboratories for Integrative Neuroscience and Endocrinology, School of Clinical Sciences, Faculty of Healthy Sciences, University of Bristol, Whitson street, Bristol, BS1 3NY, UK
Department of Neurology, Chonnam National University Medical School, Gwangju, 61469, South Korea


  1. Selkoe DJ. Alzheimer's disease: genes, proteins, and therapy. Physiol Rev. 2001;81(2):741–66.PubMedView ArticleGoogle Scholar
  2. Ballard C, Gauthier S, Corbett A, Brayne C, Aarsland D, Jones E. Alzheimer's disease. Lancet. 2011;377(9770):1019–31.PubMedView ArticleGoogle Scholar
  3. Alzheimer's Association National Plan Milestone W, Fargo KN, Aisen P, Albert M, Au R, Corrada MM, et al. 2014 report on the milestones for the US National Plan to address Alzheimer's disease. Alzheimers Dement. 2014;10(5 Suppl):S430–52.Google Scholar
  4. Gulland A. Number of people with dementia will reach 65.7 million by 2030, says report. BMJ. 2012;344:e2604.PubMedView ArticleGoogle Scholar
  5. Zhang G, Xie Y, Wang W, Feng X, Jia J. Clinical characterization of an APP mutation (V717I) in five Han Chinese families with early-onset Alzheimer's disease. J Neurol Sci. 2016; doi:10.1016/j.jns.2016.10.039.
  6. Cuccaro ML, Carney RM, Zhang Y, Bohm C, Kunkle BW, Vardarajan BN, et al. SORL1 mutations in early- and late-onset Alzheimer disease. Neurol Genet. 2016;2(6):e116.PubMedPubMed CentralView ArticleGoogle Scholar
  7. Canerina-Amaro A, Hernandez-Abad LG, Ferrer I, Quinto-Alemany D, Mesa-Herrera F, Ferri C, et al. Lipid raft ER signalosome malfunctions in menopause and Alzheimer's disease. Front Biosci (Schol Ed). 2017;9:111–26.View ArticleGoogle Scholar
  8. Dong HK, Gim JA, Yeo SH, Kim HS. Integrated late onset Alzheimer's disease (LOAD) susceptibility genes: cholesterol metabolism and trafficking perspectives. Gene. 2016; doi:10.1016/j.gene.2016.10.022.
  9. Loffler T, Flunkert S, Temmel M, Hutter-Paier B. Decreased plasma Abeta in Hyperlipidemic APPSL transgenic mice is associated with BBB dysfunction. Front Neurosci. 2016;10:232.PubMedPubMed CentralView ArticleGoogle Scholar
  10. Zhou X, Li Y, Shi X, Ma C. An overview on therapeutics attenuating amyloid beta level in Alzheimer's disease: targeting neurotransmission, inflammation, oxidative stress and enhanced cholesterol levels. Am J Transl Res. 2016;8(2):246–69.PubMedPubMed CentralGoogle Scholar
  11. Thomas J, Thomas CJ, Radcliffe J, Itsiopoulos C. Omega-3 fatty acids in early prevention of inflammatory neurodegenerative disease: a focus on Alzheimer's disease. Biomed Res Int. 2015;2015:172801.PubMedPubMed CentralGoogle Scholar
  12. Domenico FD, Tramutola A, Butterfield DA. Role of 4-Hydroxy-2-Nonenal (Hne) in the pathogenesis of Alzheimer disease and other selected age-related neurodegenerative disorders. Free Radic Biol Med. 2016; doi:10.1016/j.freeradbiomed.2016.10.490.
  13. Li H, Lv CL, Yang CS, Wei DF, Chen KW, Li SW, et al. SORL1 rs1699102 polymorphism modulates age-related cognitive decline and gray matter volume reduction in non-demented individuals. Eur J Neurol. 2016; doi:10.1111/ene.13182.
  14. Na HK, Kang DR, Kim S, Seo SW, Heilman KM, Noh Y, et al. Malignant progression in parietal-dominant atrophy subtype of Alzheimer's disease occurs independent of onset age. Neurobiol Aging. 2016;47:149–56.PubMedView ArticleGoogle Scholar
  15. Dominguez LJ, Barbagallo M. Dietary approaches and supplements in the prevention of cognitive decline and Alzheimer's disease. Curr Pharm Des. 2016;22(6):688–700.PubMedView ArticleGoogle Scholar
  16. Ashe KH, Zahs KR. Probing the biology of Alzheimer's disease in mice. Neuron. 2010;66(5):631–45.PubMedPubMed CentralView ArticleGoogle Scholar
  17. de la Monte SM, Wands JR. Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis. 2005;7(1):45–61.PubMedView ArticleGoogle Scholar
  18. Craft S. Alzheimer disease: insulin resistance and AD--extending the translational path. Nat Rev Neurol. 2012;8(7):360–2.PubMedView ArticleGoogle Scholar
  19. Biessels GJ, Staekenborg S, Brunner E, Brayne C, Scheltens P. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol. 2006;5(1):64–74.PubMedView ArticleGoogle Scholar
  20. Huang CC, Chung CM, Leu HB, Lin LY, Chiu CC, Hsu CY, et al. Diabetes mellitus and the risk of Alzheimer's disease: a nationwide population-based study. PLoS One. 2014;9(1):e87095.PubMedPubMed CentralView ArticleGoogle Scholar
  21. Ding J, Strachan MW, Reynolds RM, Frier BM, Deary IJ, Fowkes FG, et al. Diabetic retinopathy and cognitive decline in older people with type 2 diabetes: the Edinburgh type 2 diabetes study. Diabetes. 2010;59(11):2883–9.PubMedPubMed CentralView ArticleGoogle Scholar
  22. Profenno LA, Porsteinsson AP, Faraone SV. Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders. Biol Psychiatry. 2010;67(6):505–12.PubMedView ArticleGoogle Scholar
  23. de la Monte SM, Wands JR. Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol. 2008;2(6):1101–13.PubMedPubMed CentralView ArticleGoogle Scholar
  24. Lester-Coll N, Rivera EJ, Soscia SJ, Doiron K, Wands JR, de la Monte SM. Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis. 2006;9(1):13–33.PubMedView ArticleGoogle Scholar
  25. Lin B, Hasegawa Y, Takane K, Koibuchi N, Cao C, Kim-Mitsuyama S. High-Fat-Diet Intake Enhances Cerebral Amyloid Angiopathy and Cognitive Impairment in a Mouse Model of Alzheimer's Disease, Independently of Metabolic Disorders. J Am Heart Assoc. 2016;5(6):e003154. doi:10.1161/JAHA.115.003154.
  26. Wiechmann AF, Sherry DM. Role of melatonin and its receptors in the vertebrate retina. Int Rev Cell Mol Biol. 2013;300:211–42.PubMedView ArticleGoogle Scholar
  27. Chen CY, Logan RW, Ma T, Lewis DA, Tseng GC, Sibille E, et al. Effects of aging on circadian patterns of gene expression in the human prefrontal cortex. Proc Natl Acad Sci U S A. 2016;113(1):206–11.PubMedView ArticleGoogle Scholar
  28. Manchester LC, Coto-Montes A, Boga JA, Andersen LP, Zhou Z, Galano A, et al. Melatonin: an ancient molecule that makes oxygen metabolically tolerable. J Pineal Res. 2015;59(4):403–19.PubMedView ArticleGoogle Scholar
  29. Moretti R, Zanin A, Pansiot J, Spiri D, Manganozzi L, Kratzer I, et al. Melatonin reduces excitotoxic blood-brain barrier breakdown in neonatal rats. Neuroscience. 2015;311:382–97.PubMedView ArticleGoogle Scholar
  30. Hardeland R, Cardinali DP, Brown GM, Pandi-Perumal SR. Melatonin and brain inflammaging. Prog Neurobiol. 2015;127–128:46–63.PubMedView ArticleGoogle Scholar
  31. Pistacchi M, Gioulis M, Contin F, Sanson F, Marsala SZ. Sleep disturbance and cognitive disorder: epidemiological analysis in a cohort of 263 patients. Neurol Sci. 2014;35(12):1955–62.PubMedView ArticleGoogle Scholar
  32. Cipriani G, Lucetti C, Danti S, Nuti A. Sleep disturbances and dementia. Psychogeriatrics. 2015;15(1):65–74.PubMedView ArticleGoogle Scholar
  33. Song Q, Feng G, Huang Z, Chen X, Chen Z, Ping Y. Aberrant axonal Arborization of PDF neurons induced by Abeta42-mediated JNK activation underlies sleep disturbance in an Alzheimer's model. Mol Neurobiol. 2016; doi:10.1007/s12035-016-0165-z.
  34. Ooms S, Ju YE. Treatment of sleep disorders in dementia. Curr Treat Options Neurol. 2016;18(9):40.PubMedPubMed CentralView ArticleGoogle Scholar
  35. Zhang W, Chen XY, Su SW, Jia QZ, Ding T, Zhu ZN, et al. Exogenous melatonin for sleep disorders in neurodegenerative diseases: a meta-analysis of randomized clinical trials. Neurol Sci. 2016;37(1):57–65.PubMedView ArticleGoogle Scholar
  36. Wu YH, Swaab DF. The human pineal gland and melatonin in aging and Alzheimer's disease. J Pineal Res. 2005;38(3):145–52.PubMedView ArticleGoogle Scholar
  37. Zhou JN, Liu RY, Kamphorst W, Hofman MA, Swaab DF. Early neuropathological Alzheimer's changes in aged individuals are accompanied by decreased cerebrospinal fluid melatonin levels. J Pineal Res. 2003;35(2):125–30.PubMedView ArticleGoogle Scholar
  38. Rudnitskaya EA, Muraleva NA, Maksimova KY, Kiseleva E, Kolosova NG, Stefanova NA. Melatonin attenuates memory impairment, amyloid-beta accumulation, and neurodegeneration in a rat model of sporadic Alzheimer's disease. J Alzheimers Dis. 2015;47(1):103–16.PubMedView ArticleGoogle Scholar
  39. Ali T, Kim MO. Melatonin ameliorates amyloid beta-induced memory deficits, tau hyperphosphorylation and neurodegeneration via PI3/Akt/GSk3beta pathway in the mouse hippocampus. J Pineal Res. 2015;59(1):47–59.PubMedView ArticleGoogle Scholar
  40. Stefanova NA, Maksimova KY, Kiseleva E, Rudnitskaya EA, Muraleva NA, Kolosova NG. Melatonin attenuates impairments of structural hippocampal neuroplasticity in OXYS rats during active progression of Alzheimer's disease-like pathology. J Pineal Res. 2015;59(2):163–77.PubMedView ArticleGoogle Scholar
  41. Alluri H, Wilson RL, Anasooya Shaji C, Wiggins-Dohlvik K, Patel S, Liu Y, et al. Melatonin preserves blood-brain barrier integrity and permeability via matrix metalloproteinase-9 inhibition. PLoS One. 2016;11(5):e0154427.PubMedPubMed CentralView ArticleGoogle Scholar
  42. Peschke E, Frese T, Chankiewitz E, Peschke D, Preiss U, Schneyer U, et al. Diabetic Goto Kakizaki rats as well as type 2 diabetic patients show a decreased diurnal serum melatonin level and an increased pancreatic melatonin-receptor status. J Pineal Res. 2006;40(2):135–43.PubMedView ArticleGoogle Scholar
  43. Contreras-Alcantara S, Baba K, Tosini G. Removal of melatonin receptor type 1 induces insulin resistance in the mouse. Obesity (Silver Spring). 2010;18(9):1861–3.View ArticleGoogle Scholar
  44. Rubio-Sastre P, Scheer FA, Gomez-Abellan P, Madrid JA, Garaulet M. Acute melatonin administration in humans impairs glucose tolerance in both the morning and evening. Sleep. 2014;37(10):1715–9.PubMedPubMed CentralView ArticleGoogle Scholar
  45. Kendall DM, Bergenstal RM. Comprehensive management of patients with type 2 diabetes: establishing priorities of care. Am J Manag Care. 2001;7(10 Suppl):S327–43–quiz S44–8.Google Scholar
  46. Bixler E. Sleep and society: an epidemiological perspective. Sleep Med. 2009;10(Suppl 1):S3–6.PubMedView ArticleGoogle Scholar
  47. Scheer FA, Hilton MF, Mantzoros CS, Shea SA. Adverse metabolic and cardiovascular consequences of circadian misalignment. Proc Natl Acad Sci U S A. 2009;106(11):4453–8.PubMedPubMed CentralView ArticleGoogle Scholar
  48. Mogi M, Horiuchi M. Neurovascular coupling in cognitive impairment associated with diabetes mellitus. Circ J. 2011;75(5):1042–8.PubMedView ArticleGoogle Scholar
  49. Cheng G, Huang C, Deng H, Wang H. Diabetes as a risk factor for dementia and mild cognitive impairment: a meta-analysis of longitudinal studies. Intern Med J. 2012;42(5):484–91.PubMedView ArticleGoogle Scholar
  50. Umegaki H. Neurodegeneration in diabetes mellitus. Adv Exp Med Biol. 2012;724:258–65.PubMedView ArticleGoogle Scholar
  51. Holscher C. Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans. 2011;39(4):891–7.PubMedView ArticleGoogle Scholar
  52. Tsuruta R, Fujita M, Ono T, Koda Y, Koga Y, Yamamoto T, et al. Hyperglycemia enhances excessive superoxide anion radical generation, oxidative stress, early inflammation, and endothelial injury in forebrain ischemia/reperfusion rats. Brain Res. 2010;1309:155–63.PubMedView ArticleGoogle Scholar
  53. Fukasawa R, Hanyu H, Namioka N, Hatanaka H, Sato T, Sakurai H. Elevated inflammatory markers in diabetes-related dementia. Geriatr Gerontol Int. 2014;14(1):229–31.PubMedView ArticleGoogle Scholar
  54. Banks WA, Owen JB, Erickson MA. Insulin in the brain: there and back again. Pharmacol Ther. 2012;136(1):82–93.PubMedPubMed CentralView ArticleGoogle Scholar
  55. Shao B, Bayraktutan U. Hyperglycaemia promotes cerebral barrier dysfunction through activation of protein kinase C-beta. Diabetes Obes Metab. 2013;15(11):993–9.PubMedView ArticleGoogle Scholar
  56. Baker LD, Cross DJ, Minoshima S, Belongia D, Watson GS, Craft S. Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes. Arch Neurol. 2011;68(1):51–7.PubMedView ArticleGoogle Scholar
  57. Talbot K, Wang HY, Kazi H, Han LY, Bakshi KP, Stucky A, et al. Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest. 2012;122(4):1316–38.PubMedPubMed CentralView ArticleGoogle Scholar
  58. de la Monte SM, Longato L, Tong M, Wands JR. Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs. 2009;10(10):1049–60.PubMedPubMed CentralGoogle Scholar
  59. Nelson TJ, Sun MK, Hongpaisan J, Alkon DL. Insulin, PKC signaling pathways and synaptic remodeling during memory storage and neuronal repair. Eur J Pharmacol. 2008;585(1):76–87.PubMedView ArticleGoogle Scholar
  60. Steen E, Terry BM, Rivera EJ, Cannon JL, Neely TR, Tavares R, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis. 2005;7(1):63–80.PubMedView ArticleGoogle Scholar
  61. Havrankova J, Roth J, Brownstein M. Insulin receptors are widely distributed in the central nervous system of the rat. Nature. 1978;272(5656):827–9.PubMedView ArticleGoogle Scholar
  62. Boura-Halfon S, Zick Y. Phosphorylation of IRS proteins, insulin action, and insulin resistance. Am J Physiol Endocrinol Metab. 2009;296(4):E581–91.PubMedView ArticleGoogle Scholar
  63. Frolich L, Blum-Degen D, Bernstein HG, Engelsberger S, Humrich J, Laufer S, et al. Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna). 1998;105(4–5):423–38.View ArticleGoogle Scholar
  64. Zhao WQ, Alkon DL. Role of insulin and insulin receptor in learning and memory. Mol Cell Endocrinol. 2001;177(1–2):125–34.PubMedView ArticleGoogle Scholar
  65. Kern W, Peters A, Fruehwald-Schultes B, Deininger E, Born J, Fehm HL. Improving influence of insulin on cognitive functions in humans. Neuroendocrinology. 2001;74(4):270–80.PubMedView ArticleGoogle Scholar
  66. Gil-Bea FJ, Solas M, Solomon A, Mugueta C, Winblad B, Kivipelto M, et al. Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J Alzheimers Dis. 2010;22(2):405–13.PubMedView ArticleGoogle Scholar
  67. Xu J, Yeon JE, Chang H, Tison G, Chen GJ, Wands J, et al. Ethanol impairs insulin-stimulated neuronal survival in the developing brain: role of PTEN phosphatase. J Biol Chem. 2003;278(29):26929–37.PubMedView ArticleGoogle Scholar
  68. Schioth HB, Craft S, Brooks SJ, Frey WH 2nd, Benedict C. Brain insulin signaling and Alzheimer's disease: current evidence and future directions. Mol Neurobiol. 2012;46(1):4–10.PubMedView ArticleGoogle Scholar
  69. Ahmed S, Mahmood Z, Zahid S. Linking insulin with Alzheimer's disease: emergence as type III diabetes. Neurol Sci. 2015;36(10):1763–9.PubMedView ArticleGoogle Scholar
  70. Yin F, Jiang T, Cadenas E. Metabolic triad in brain aging: mitochondria, insulin/IGF-1 signalling and JNK signalling. Biochem Soc Trans. 2013;41(1):101–5.PubMedView ArticleGoogle Scholar
  71. Hoyer S. Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol. 2004;490(1–3):115–25.PubMedView ArticleGoogle Scholar
  72. Schubert M, Brazil DP, Burks DJ, Kushner JA, Ye J, Flint CL, et al. Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci. 2003;23(18):7084–92.PubMedView ArticleGoogle Scholar
  73. Schubert M, Gautam D, Surjo D, Ueki K, Baudler S, Schubert D, et al. Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A. 2004;101(9):3100–5.PubMedPubMed CentralView ArticleGoogle Scholar
  74. Balasubramanian AS. Role of phosphorylation and dephosphorylation in the functions of mannose-6-phosphate/insulin like growth factor II receptor. Indian J Biochem Biophys. 1997;34(1–2):178–80.PubMedGoogle Scholar
  75. Dricu A, Carlberg M, Wang M, Larsson O. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res. 1997;57(3):543–8.PubMedGoogle Scholar
  76. Doble BW, Woodgett JR. GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci. 2003;116(Pt 7):1175–86.PubMedPubMed CentralView ArticleGoogle Scholar
  77. Grilli M, Ferrari Toninelli G, Uberti D, Spano P, Memo M. Alzheimer's disease linking neurodegeneration with neurodevelopment. Funct Neurol. 2003;18(3):145–8.PubMedGoogle Scholar
  78. Bhat R, Xue Y, Berg S, Hellberg S, Ormo M, Nilsson Y, et al. Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418. J Biol Chem. 2003;278(46):45937–45.PubMedView ArticleGoogle Scholar
  79. Watson GS, Craft S. The role of insulin resistance in the pathogenesis of Alzheimer's disease: implications for treatment. CNS Drugs. 2003;17(1):27–45.PubMedView ArticleGoogle Scholar
  80. de la Monte SM. Brain insulin resistance and deficiency as therapeutic targets in Alzheimer's disease. Curr Alzheimer Res. 2012;9(1):35–66.PubMedPubMed CentralView ArticleGoogle Scholar
  81. de la Monte S, Derdak Z, Wands JR. Alcohol, insulin resistance and the liver-brain axis. J Gastroenterol Hepatol. 2012;27(Suppl 2):33–41.PubMedPubMed CentralView ArticleGoogle Scholar
  82. Alagiakrishnan K, Sankaralingam S, Ghosh M, Mereu L, Senior P. Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease. Discov Med. 2013;16(90):277–86.PubMedGoogle Scholar
  83. Akter K, Lanza EA, Martin SA, Myronyuk N, Rua M, Raffa RB. Diabetes mellitus and Alzheimer's disease: shared pathology and treatment? Br J Clin Pharmacol. 2011;71(3):365–76.PubMedPubMed CentralView ArticleGoogle Scholar
  84. Tong M, de la Monte SM. Mechanisms of ceramide-mediated neurodegeneration. J Alzheimers Dis. 2009;16(4):705–14.PubMedPubMed CentralView ArticleGoogle Scholar
  85. de la Monte SM, Tong M. Mechanisms of nitrosamine-mediated neurodegeneration: potential relevance to sporadic Alzheimer's disease. J Alzheimers Dis. 2009;17(4):817–25.PubMedPubMed CentralView ArticleGoogle Scholar
  86. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR. Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis. 2006;10(1):89–109.PubMedView ArticleGoogle Scholar
  87. Craft S, Watson GS. Insulin and neurodegenerative disease: shared and specific mechanisms. Lancet Neurol. 2004;3(3):169–78.PubMedView ArticleGoogle Scholar
  88. Willette AA, Johnson SC, Birdsill AC, Sager MA, Christian B, Baker LD, et al. Insulin resistance predicts brain amyloid deposition in late middle-aged adults. Alzheimers Dement. 2015;11(5):504–10. e1PubMedView ArticleGoogle Scholar
  89. Ravona-Springer R, Moshier E, Schmeidler J, Godbold J, Akrivos J, Rapp M, et al. Changes in glycemic control are associated with changes in cognition in non-diabetic elderly. J Alzheimers Dis. 2012;30(2):299–309.PubMedPubMed CentralView ArticleGoogle Scholar
  90. Ravona-Springer R, Heymann A, Schmeidler J, Moshier E, Godbold J, Sano M, et al. Trajectories in glycemic control over time are associated with cognitive performance in elderly subjects with type 2 diabetes. PLoS One. 2014;9(6):e97384.PubMedPubMed CentralView ArticleGoogle Scholar
  91. Strachan MW, Reynolds RM, Marioni RE, Price JF. Cognitive function, dementia and type 2 diabetes mellitus in the elderly. Nat Rev Endocrinol. 2011;7(2):108–14.PubMedView ArticleGoogle Scholar
  92. Starr JM, Wardlaw J, Ferguson K, MacLullich A, Deary IJ, Marshall I. Increased blood-brain barrier permeability in type II diabetes demonstrated by gadolinium magnetic resonance imaging. J Neurol Neurosurg Psychiatry. 2003;74(1):70–6.PubMedPubMed CentralView ArticleGoogle Scholar
  93. Hawkins BT, Lundeen TF, Norwood KM, Brooks HL, Egleton RD. Increased blood-brain barrier permeability and altered tight junctions in experimental diabetes in the rat: contribution of hyperglycaemia and matrix metalloproteinases. Diabetologia. 2007;50(1):202–11.PubMedView ArticleGoogle Scholar
  94. Chehade JM, Haas MJ, Mooradian AD. Diabetes-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1) expression. Neurochem Res. 2002;27(3):249–52.PubMedView ArticleGoogle Scholar
  95. de la Monte SM. Therapeutic targets of brain insulin resistance in sporadic Alzheimer's disease. Front Biosci (Elite Ed). 2012;4:1582–605.View ArticleGoogle Scholar
  96. de la Monte SM. Contributions of brain insulin resistance and deficiency in amyloid-related neurodegeneration in Alzheimer's disease. Drugs. 2012;72(1):49–66.PubMedPubMed CentralView ArticleGoogle Scholar
  97. Hawkins BT, Davis TP. The blood-brain barrier/neurovascular unit in health and disease. Pharmacol Rev. 2005;57(2):173–85.PubMedView ArticleGoogle Scholar
  98. Thorens B, Mueckler M. Glucose transporters in the 21st century. Am J Physiol Endocrinol Metab. 2010;298(2):E141–5.PubMedView ArticleGoogle Scholar
  99. Brockmann K. The expanding phenotype of GLUT1-deficiency syndrome. Brain and Development. 2009;31(7):545–52.PubMedView ArticleGoogle Scholar
  100. Hou WK, Xian YX, Zhang L, Lai H, Hou XG, Xu YX, et al. Influence of blood glucose on the expression of glucose trans-porter proteins 1 and 3 in the brain of diabetic rats. Chin Med J. 2007;120(19):1704–9.PubMedGoogle Scholar
  101. Huber JD, VanGilder RL, Houser KA. Streptozotocin-induced diabetes progressively increases blood-brain barrier permeability in specific brain regions in rats. Am J Physiol Heart Circ Physiol. 2006;291(6):H2660–8.PubMedView ArticleGoogle Scholar
  102. Acharya NK, Levin EC, Clifford PM, Han M, Tourtellotte R, Chamberlain D, et al. Diabetes and hypercholesterolemia increase blood-brain barrier permeability and brain amyloid deposition: beneficial effects of the LpPLA2 inhibitor darapladib. J Alzheimers Dis. 2013;35(1):179–98.PubMedView ArticleGoogle Scholar
  103. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res. 2010;107(9):1058–70.PubMedPubMed CentralView ArticleGoogle Scholar
  104. Okouchi M, Okayama N, Alexander JS, Aw TY. NRF2-dependent glutamate-L-cysteine ligase catalytic subunit expression mediates insulin protection against hyperglycemia- induced brain endothelial cell apoptosis. Curr Neurovasc Res. 2006;3(4):249–61.PubMedView ArticleGoogle Scholar
  105. Duelli R, Maurer MH, Staudt R, Heiland S, Duembgen L, Kuschinsky W. Increased cerebral glucose utilization and decreased glucose transporter Glut1 during chronic hyperglycemia in rat brain. Brain Res. 2000;858(2):338–47.PubMedView ArticleGoogle Scholar
  106. Schrijvers EM, Witteman JC, Sijbrands EJ, Hofman A, Koudstaal PJ, Breteler MM. Insulin metabolism and the risk of Alzheimer disease: the Rotterdam study. Neurology. 2010;75(22):1982–7.PubMedPubMed CentralView ArticleGoogle Scholar
  107. Tucsek Z, Toth P, Sosnowska D, Gautam T, Mitschelen M, Koller A, et al. Obesity in aging exacerbates blood-brain barrier disruption, neuroinflammation, and oxidative stress in the mouse hippocampus: effects on expression of genes involved in beta-amyloid generation and Alzheimer's disease. J Gerontol A Biol Sci Med Sci. 2014;69(10):1212–26.PubMedView ArticleGoogle Scholar
  108. Kovac A, Zilkova M, Deli MA, Zilka N, Novak M. Human truncated tau is using a different mechanism from amyloid-beta to damage the blood-brain barrier. J Alzheimers Dis. 2009;18(4):897–906.PubMedView ArticleGoogle Scholar
  109. Blair LJ, Frauen HD, Zhang B, Nordhues BA, Bijan S, Lin YC, et al. Tau depletion prevents progressive blood-brain barrier damage in a mouse model of tauopathy. Acta Neuropathol Commun. 2015;3:8.PubMedPubMed CentralView ArticleGoogle Scholar
  110. Sabzichi M, Samadi N, Mohammadian J, Hamishehkar H, Akbarzadeh M, Molavi O. Sustained release of melatonin: a novel approach in elevating efficacy of tamoxifen in breast cancer treatment. Colloids Surf B Biointerfaces. 2016;145:64–71.PubMedView ArticleGoogle Scholar
  111. Zetner D, Andersen LP, Rosenberg J. Pharmacokinetics of alternative administration routes of melatonin: a systematic review. Drug Res (Stuttg). 2016;66(4):169–73.Google Scholar
  112. El-Gammal MY, Salem AS, Anees MM, Tawfik MA. Clinical and radiographic evaluation of immediate loaded dental implants with local application of melatonin: a preliminary randomized controlled clinical trial. J Oral Implantol. 2016;42(2):119–25.PubMedView ArticleGoogle Scholar
  113. Zenaro E, Piacentino G, Constantin G. The blood-brain barrier in Alzheimer's disease. Neurobiol Dis. 2016; doi:10.1016/j.nbd.2016.07.007.
  114. Olcese JM, Cao C, Mori T, Mamcarz MB, Maxwell A, Runfeldt MJ, et al. Protection against cognitive deficits and markers of neurodegeneration by long-term oral administration of melatonin in a transgenic model of Alzheimer disease. J Pineal Res. 2009;47(1):82–96.PubMedView ArticleGoogle Scholar
  115. Zhou J, Zhang S, Zhao X, Wei T. Melatonin impairs NADPH oxidase assembly and decreases superoxide anion production in microglia exposed to amyloid-beta1-42. J Pineal Res. 2008;45(2):157–65.PubMedView ArticleGoogle Scholar
  116. Buendia I, Egea J, Parada E, Navarro E, Leon R, Rodriguez-Franco MI, et al. The melatonin-N,N-dibenzyl(N-methyl)amine hybrid ITH91/IQM157 affords neuroprotection in an in vitro Alzheimer's model via hemo-oxygenase-1 induction. ACS Chem Neurosci. 2015;6(2):288–96.PubMedView ArticleGoogle Scholar
  117. Ali T, Badshah H, Kim TH, Kim MO. Melatonin attenuates D-galactose-induced memory impairment, neuroinflammation and neurodegeneration via RAGE/NF-K B/JNK signaling pathway in aging mouse model. J Pineal Res. 2015;58(1):71–85.PubMedView ArticleGoogle Scholar
  118. Galano A, Tan DX, Reiter RJ. On the free radical scavenging activities of melatonin's metabolites. AFMK and AMK J Pineal Res. 2013;54(3):245–57.PubMedGoogle Scholar
  119. Hardeland R, Tan DX, Reiter RJ. Kynuramines, metabolites of melatonin and other indoles: the resurrection of an almost forgotten class of biogenic amines. J Pineal Res. 2009;47(2):109–26.PubMedView ArticleGoogle Scholar
  120. Zhang S, Wang P, Ren L, Hu C, Bi J. Protective effect of melatonin on soluble Abeta1-42-induced memory impairment, astrogliosis, and synaptic dysfunction via the Musashi1/Notch1/Hes1 signaling pathway in the rat hippocampus. Alzheimers Res Ther. 2016;8(1):40.PubMedPubMed CentralView ArticleGoogle Scholar
  121. Gutierrez-Cuesta J, Tajes M, Jimenez A, Coto-Montes A, Camins A, Pallas M. Evaluation of potential pro-survival pathways regulated by melatonin in a murine senescence model. J Pineal Res. 2008;45(4):497–505.PubMedView ArticleGoogle Scholar
  122. Wu YH, Feenstra MG, Zhou JN, Liu RY, Torano JS, Van Kan HJ, et al. Molecular changes underlying reduced pineal melatonin levels in Alzheimer disease: alterations in preclinical and clinical stages. J Clin Endocrinol Metab. 2003;88(12):5898–906.PubMedView ArticleGoogle Scholar
  123. Cardinali DP, Vigo DE, Olivar N, Vidal MF, Furio AM, Brusco LI. Therapeutic application of melatonin in mild cognitive impairment. Am J Neurodegener Dis. 2012;1(3):280–91.PubMedPubMed CentralGoogle Scholar
  124. Wilhelmsen M, Amirian I, Reiter RJ, Rosenberg J, Gogenur I. Analgesic effects of melatonin: a review of current evidence from experimental and clinical studies. J Pineal Res. 2011;51(3):270–7.PubMedView ArticleGoogle Scholar
  125. Thal DR, Walter J, Saido TC, Fandrich M. Neuropathology and biochemistry of Abeta and its aggregates in Alzheimer's disease. Acta Neuropathol. 2015;129(2):167–82.PubMedView ArticleGoogle Scholar
  126. Mozaffari S, Abdollahi M. Melatonin, a promising supplement in inflammatory bowel disease: a comprehensive review of evidences. Curr Pharm Des. 2011;17(38):4372–8.PubMedView ArticleGoogle Scholar
  127. Mukda S, Panmanee J, Boontem P, Govitrapong P. Melatonin administration reverses the alteration of amyloid precursor protein-cleaving secretases expression in aged mouse hippocampus. Neurosci Lett. 2016;621:39–46.PubMedView ArticleGoogle Scholar
  128. Polimeni G, Esposito E, Bevelacqua V, Guarneri C, Cuzzocrea S. Role of melatonin supplementation in neurodegenerative disorders. Front Biosci (Landmark Ed). 2014;19:429–46.View ArticleGoogle Scholar
  129. Di Domenico F, Barone E, Perluigi M, Butterfield DA. Strategy to reduce free radical species in Alzheimer's disease: an update of selected antioxidants. Expert Rev Neurother. 2015;15(1):19–40.PubMedView ArticleGoogle Scholar
  130. Panmanee J, Nopparat C, Chavanich N, Shukla M, Mukda S, Song W, et al. Melatonin regulates the transcription of betaAPP-cleaving secretases mediated through melatonin receptors in human neuroblastoma SH-SY5Y cells. J Pineal Res. 2015;59(3):308–20.PubMedView ArticleGoogle Scholar
  131. Devine C. Melatonin: a non-benzodiazepine hypnotic in an elderly blind female with dementia. Ther Adv Psychopharmacol. 2011;1(3):89–90.PubMedPubMed CentralView ArticleGoogle Scholar
  132. Liu XJ, Yuan L, Yang D, Han WN, Li QS, Yang W, et al. Melatonin protects against amyloid-beta-induced impairments of hippocampal LTP and spatial learning in rats. Synapse. 2013;67(9):626–36.PubMedView ArticleGoogle Scholar
  133. Zhu LQ, Wang SH, Ling ZQ, Wang DL, Wang JZ. Effect of inhibiting melatonin biosynthesis on spatial memory retention and tau phosphorylation in rat. J Pineal Res. 2004;37(2):71–7.PubMedView ArticleGoogle Scholar
  134. Pulimeno P, Mannic T, Sage D, Giovannoni L, Salmon P, Lemeille S, et al. Autonomous and self-sustained circadian oscillators displayed in human islet cells. Diabetologia. 2013;56(3):497–507.PubMedView ArticleGoogle Scholar
  135. Shi SQ, Ansari TS, McGuinness OP, Wasserman DH, Johnson CH. Circadian disruption leads to insulin resistance and obesity. Curr Biol. 2013;23(5):372–81.PubMedPubMed CentralView ArticleGoogle Scholar
  136. Fonken LK, Nelson RJ. The effects of light at night on circadian clocks and metabolism. Endocr Rev. 2014;35(4):648–70.PubMedView ArticleGoogle Scholar
  137. Peschke E, Stumpf I, Bazwinsky I, Litvak L, Dralle H, Muhlbauer E. Melatonin and type 2 diabetes - a possible link? J Pineal Res. 2007;42(4):350–8.PubMedView ArticleGoogle Scholar
  138. Sakotnik A, Liebmann PM, Stoschitzky K, Lercher P, Schauenstein K, Klein W, et al. Decreased melatonin synthesis in patients with coronary artery disease. Eur Heart J. 1999;20(18):1314–7.PubMedView ArticleGoogle Scholar
  139. Staiger H, Machicao F, Schafer SA, Kirchhoff K, Kantartzis K, Guthoff M, et al. Polymorphisms within the novel type 2 diabetes risk locus MTNR1B determine beta-cell function. PLoS One. 2008;3(12):e3962.PubMedPubMed CentralView ArticleGoogle Scholar
  140. Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. Nat Genet. 2009;41(1):89–94.PubMedView ArticleGoogle Scholar
  141. Lyssenko V, Nagorny CL, Erdos MR, Wierup N, Jonsson A, Spegel P, et al. Common variant in MTNR1B associated with increased risk of type 2 diabetes and impaired early insulin secretion. Nat Genet. 2009;41(1):82–8.PubMedView ArticleGoogle Scholar
  142. Andersson EA, Holst B, Sparso T, Grarup N, Banasik K, Holmkvist J, et al. MTNR1B G24E variant associates with BMI and fasting plasma glucose in the general population in studies of 22,142 Europeans. Diabetes. 2010;59(6):1539–48.PubMedPubMed CentralView ArticleGoogle Scholar
  143. Sparso T, Bonnefond A, Andersson E, Bouatia-Naji N, Holmkvist J, Wegner L, et al. G-allele of intronic rs10830963 in MTNR1B confers increased risk of impaired fasting glycemia and type 2 diabetes through an impaired glucose-stimulated insulin release: studies involving 19,605 Europeans. Diabetes. 2009;58(6):1450–6.PubMedPubMed CentralView ArticleGoogle Scholar
  144. Kothari V, Luo Y, Tornabene T, O'Neill AM, Greene MW, Thangiah G, et al. High fat diet induces brain insulin resistance and cognitive impairment in mice. Biochim Biophys Acta. 2016; doi:10.1016/j.bbadis.2016.10.006.
  145. FangFang LH, Qin T, Li M, Ma S. Thymol improves high-fat diet-induced cognitive deficits in mice via ameliorating brain insulin resistance and upregulating NRF2/HO-1 pathway. Metab Brain Dis. 2016; doi:10.1007/s11011-016-9921-z.
  146. Guo C, Zhang S, Li JY, Ding C, Yang ZH, Chai R, et al. Chronic hyperglycemia induced via the heterozygous knockout of Pdx1 worsens neuropathological lesion in an Alzheimer mouse model. Sci Rep. 2016;6:29396.PubMedPubMed CentralView ArticleGoogle Scholar
  147. Stumpf I, Muhlbauer E, Peschke E. Involvement of the cGMP pathway in mediating the insulin-inhibitory effect of melatonin in pancreatic beta-cells. J Pineal Res. 2008;45(3):318–27.PubMedView ArticleGoogle Scholar
  148. Stumpf I, Bazwinsky I, Peschke E. Modulation of the cGMP signaling pathway by melatonin in pancreatic beta-cells. J Pineal Res. 2009;46(2):140–7.PubMedView ArticleGoogle Scholar
  149. Prokopenko I, Langenberg C, Florez JC, Saxena R, Soranzo N, Thorleifsson G, et al. Variants in MTNR1B influence fasting glucose levels. Nat Genet. 2009;41(1):77–81.PubMedView ArticleGoogle Scholar
  150. Bazwinsky-Wutschke I, Bieseke L, Muhlbauer E, Peschke E. Influence of melatonin receptor signalling on parameters involved in blood glucose regulation. J Pineal Res. 2014;56(1):82–96.PubMedView ArticleGoogle Scholar
  151. Peschke E, Bahr I, Muhlbauer E. Melatonin and pancreatic islets: interrelationships between melatonin, insulin and glucagon. Int J Mol Sci. 2013;14(4):6981–7015.PubMedPubMed CentralView ArticleGoogle Scholar
  152. Gottlieb DJ, Punjabi NM, Newman AB, Resnick HE, Redline S, Baldwin CM, et al. Association of sleep time with diabetes mellitus and impaired glucose tolerance. Arch Intern Med. 2005;165(8):863–7.PubMedView ArticleGoogle Scholar
  153. Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006;29(3):657–61.PubMedView ArticleGoogle Scholar
  154. Agil A, El-Hammadi M, Jimenez-Aranda A, Tassi M, Abdo W, Fernandez-Vazquez G, et al. Melatonin reduces hepatic mitochondrial dysfunction in diabetic obese rats. J Pineal Res. 2015;59(1):70–9.PubMedView ArticleGoogle Scholar
  155. Cano Barquilla P, Pagano ES, Jimenez-Ortega V, Fernandez-Mateos P, Esquifino AI, Cardinali DP. Melatonin normalizes clinical and biochemical parameters of mild inflammation in diet-induced metabolic syndrome in rats. J Pineal Res. 2014;57(3):280–90.PubMedView ArticleGoogle Scholar
  156. Piccinetti CC, Migliarini B, Olivotto I, Simoniello MP, Giorgini E, Carnevali O. Melatonin and peripheral circuitries: insights on appetite and metabolism in Danio Rerio. Zebrafish. 2013;10(3):275–82.PubMedPubMed CentralView ArticleGoogle Scholar
  157. Ostrowska Z, Kos-Kudla B, Swietochowska E, Marek B, Kajdaniuk D, Ciesielska-Kopacz N. Influence of pinealectomy and long-term melatonin administration on GH-IGF-I axis function in male rats. Neuro Endocrinol Lett. 2001;22(4):255–62.PubMedGoogle Scholar
  158. Vriend J, Sheppard MS, Borer KT. Melatonin increases serum growth hormone and insulin-like growth factor I (IGF-I) levels in male Syrian hamsters via hypothalamic neurotransmitters. Growth Dev Aging. 1990;54(4):165–71.PubMedGoogle Scholar
  159. Fasshauer M, Klein J, Ueki K, Kriauciunas KM, Benito M, White MF, et al. Essential role of insulin receptor substrate-2 in insulin stimulation of Glut4 translocation and glucose uptake in brown adipocytes. J Biol Chem. 2000;275(33):25494–501.PubMedView ArticleGoogle Scholar
  160. Kaburagi Y, Satoh S, Tamemoto H, Yamamoto-Honda R, Tobe K, Veki K, et al. Role of insulin receptor substrate-1 and pp60 in the regulation of insulin-induced glucose transport and GLUT4 translocation in primary adipocytes. J Biol Chem. 1997;272(41):25839–44.PubMedView ArticleGoogle Scholar
  161. O'Neill C, Kiely AP, Coakley MF, Manning S, Long-Smith CM. Insulin and IGF-1 signalling: longevity, protein homoeostasis and Alzheimer's disease. Biochem Soc Trans. 2012;40(4):721–7.PubMedView ArticleGoogle Scholar
  162. Hildreth KL, Van Pelt RE, Schwartz RS. Obesity, insulin resistance, and Alzheimer's disease. Obesity (Silver Spring). 2012;20(8):1549–57.View ArticleGoogle Scholar
  163. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, Pandi-Perumal SR. Melatonin--a pleiotropic, orchestrating regulator molecule. Prog Neurobiol. 2011;93(3):350–84.PubMedView ArticleGoogle Scholar
  164. Zanquetta MM, Seraphim PM, Sumida DH, Cipolla-Neto J, Machado UF. Calorie restriction reduces pinealectomy-induced insulin resistance by improving GLUT4 gene expression and its translocation to the plasma membrane. J Pineal Res. 2003;35(3):141–8.PubMedView ArticleGoogle Scholar
  165. Peschke E, Wolgast S, Bazwinsky I, Ponicke K, Muhlbauer E. Increased melatonin synthesis in pineal glands of rats in streptozotocin induced type 1 diabetes. J Pineal Res. 2008;45(4):439–48.PubMedView ArticleGoogle Scholar
  166. Zeevi N, Pachter J, McCullough LD, Wolfson L, Kuchel GA. The blood-brain barrier: geriatric relevance of a critical brain-body interface. J Am Geriatr Soc. 2010;58(9):1749–57.PubMedPubMed CentralView ArticleGoogle Scholar
  167. Persidsky Y, Ramirez SH, Haorah J, Kanmogne GD. Blood-brain barrier: structural components and function under physiologic and pathologic conditions. J NeuroImmune Pharmacol. 2006;1(3):223–36.PubMedView ArticleGoogle Scholar
  168. Lovell MA, Markesbery WR. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J Neurosci Res. 2007;85(14):3036–40.PubMedView ArticleGoogle Scholar
  169. Osawa A, Maeshima S, Shimamoto Y, Maeshima E, Sekiguchi E, Kakishita K, et al. Relationship between cognitive function and regional cerebral blood flow in different types of dementia. Disabil Rehabil. 2004;26(12):739–45.PubMedView ArticleGoogle Scholar
  170. Fouillioux C, Contreras F, Lares M, Cano R, Leal E, Arraiz N, et al. Metabolic and hemodynamic markers of endothelial dysfunction in patients with hypertension and patients with type 2 diabetes during the cold pressor test. Am J Ther. 2008;15(4):389–96.PubMedView ArticleGoogle Scholar
  171. Riva CE, Logean E, Falsini B. Visually evoked hemodynamical response and assessment of neurovascular coupling in the optic nerve and retina. Prog Retin Eye Res. 2005;24(2):183–215.PubMedView ArticleGoogle Scholar
  172. Oltman CL, Kleinschmidt TL, Davidson EP, Coppey LJ, Lund DD, Yorek MA. Treatment of cardiovascular dysfunction associated with the metabolic syndrome and type 2 diabetes. Vasc Pharmacol. 2008;48(1):47–53.View ArticleGoogle Scholar
  173. Ryan CM, Geckle MO, Orchard TJ. Cognitive efficiency declines over time in adults with type 1 diabetes: effects of micro- and macrovascular complications. Diabetologia. 2003;46(7):940–8.PubMedView ArticleGoogle Scholar
  174. Ryan CM. Diabetes, aging, and cognitive decline. Neurobiol Aging. 2005;26(Suppl 1):21–5.PubMedView ArticleGoogle Scholar
  175. Nelson PT, Smith CD, Abner EA, Schmitt FA, Scheff SW, Davis GJ, et al. Human cerebral neuropathology of type 2 diabetes mellitus. Biochim Biophys Acta. 2009;1792(5):454–69.PubMedView ArticleGoogle Scholar
  176. Ristow M. Neurodegenerative disorders associated with diabetes mellitus. J Mol Med (Berl). 2004;82(8):510–29.View ArticleGoogle Scholar
  177. Haorah J, Schall K, Ramirez SH, Persidsky Y. Activation of protein tyrosine kinases and matrix metalloproteinases causes blood-brain barrier injury: novel mechanism for neurodegeneration associated with alcohol abuse. Glia. 2008;56(1):78–88.PubMedPubMed CentralView ArticleGoogle Scholar
  178. Balakumar P, Chakkarwar VA, Krishan P, Singh M. Vascular endothelial dysfunction: a tug of war in diabetic nephropathy? Biomed Pharmacother. 2009;63(3):171–9.PubMedView ArticleGoogle Scholar
  179. Jumnongprakhon P, Govitrapong P, Tocharus C, Tocharus J. Melatonin promotes blood-brain barrier integrity in methamphetamine-induced inflammation in primary rat brain microvascular endothelial cells. Brain Res. 1646;2016:182–92.Google Scholar
  180. Jumnongprakhon P, Govitrapong P, Tocharus C, Tocharus J. Inhibitory effect of melatonin on cerebral endothelial cells dysfunction induced by methamphetamine via NADPH oxidase-2. Brain Res. 1650;2016:84–92.Google Scholar
  181. Song J, Kang SM, Lee WT, Park KA, Lee KM, Lee JE. The beneficial effect of melatonin in brain endothelial cells against oxygen-glucose deprivation followed by reperfusion-induced injury. Oxidative Med Cell Longev. 2014;2014:639531.Google Scholar
  182. Turgut M, Erdogan S, Ergin K, Serter M. Melatonin ameliorates blood-brain barrier permeability, glutathione, and nitric oxide levels in the choroid plexus of the infantile rats with kaolin-induced hydrocephalus. Brain Res. 2007;1175:117–25.PubMedView ArticleGoogle Scholar
  183. Chen TY, Lee MY, Chen HY, Kuo YL, Lin SC, Wu TS, et al. Melatonin attenuates the postischemic increase in blood-brain barrier permeability and decreases hemorrhagic transformation of tissue-plasminogen activator therapy following ischemic stroke in mice. J Pineal Res. 2006;40(3):242–50.PubMedView ArticleGoogle Scholar
  184. Xie M, Hu A, Luo Y, Sun W, Hu X, Tang S. Interleukin-4 and melatonin ameliorate high glucose and interleukin-1beta stimulated inflammatory reaction in human retinal endothelial cells and retinal pigment epithelial cells. Mol Vis. 2014;20:921–8.PubMedPubMed CentralGoogle Scholar


© The Author(s). 2017